Universität zu Köln

Holtick, Udo, Shimabukuro-Vornhagen, Alexander ORCID: 0000-0002-2351-7294, Chakupurakal, Geothy, Theurich, Sebastian ORCID: 0000-0001-5706-8258, Leitzke, Silke, Burst, Anke, Hallek, Michael, von Bergwelt-Baildon, Michael, Scheid, Christof and Chemnitz, Jens M. (2016). FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. Eur. J. Haematol., 96 (5). S. 475 - 483. HOBOKEN: WILEY. ISSN 1600-0609

Full text not available from this repository.

Abstract

Reduced-intensity conditioning regimens have demonstrated lower toxicity but increased relapse rates in the context of allogeneic hematopoietic stem cell transplantation (aSCT) for patients with acute myelogenous leukemia (AML). The FLAMSA- reduced-intensity conditioning (RIC) regimen, combining a cytoreductive and a transplant-conditioning part, has been described to be efficacious in patients with refractory disease. We retrospectively analyzed clinical data of 130 patients with AML after aSCT following FLAMSA RIC at our center. The median follow-up was 37 (10-125) months. The 4-yr overall and disease-free survival rates of the whole cohort were 45% and 40%. Cumulative incidence of relapse was 29%, 35%, and 40% at 1, 2, and 4yr. There were no significant differences regarding overall and disease-free survival for patients transplanted in CR1, CR2, or primary induction failure (PIF). Patients with refractory disease after salvage therapy had significantly lower disease-free and overall survival (OS). Disease-free and OS rates were also significantly decreased in patients with 10% or more BLASTS at transplant. non-relapse mortality was 15%, 19%, and 20% at 1, 2, and 4yr and similar in all cohorts. These data underscore the potency of the FLAMSA RIC regimen for patients with AML especially with PIF. The decision for re-induction therapy prior to aSCT in relapsed patients has to be weighed against the potential toxicity of this approach and might be influenced by the amount of leukemic BLASTS present. Only randomised trials will answer this important question.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Holtick, Udo UNSPECIFIED UNSPECIFIED UNSPECIFIED Shimabukuro-Vornhagen, Alexander UNSPECIFIED orcid.org/0000-0002-2351-7294 UNSPECIFIED Chakupurakal, Geothy UNSPECIFIED UNSPECIFIED UNSPECIFIED Theurich, Sebastian UNSPECIFIED orcid.org/0000-0001-5706-8258 UNSPECIFIED Leitzke, Silke UNSPECIFIED UNSPECIFIED UNSPECIFIED Burst, Anke UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED von Bergwelt-Baildon, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Scheid, Christof UNSPECIFIED UNSPECIFIED UNSPECIFIED Chemnitz, Jens M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-277592
DOI:	10.1111/ejh.12615
Journal or Publication Title:	Eur. J. Haematol.
Volume:	96
Number:	5
Page Range:	S. 475 - 483
Date:	2016
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1600-0609
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; CHEMOTHERAPY; REGIMEN; RELAPSE; CYCLOPHOSPHAMIDE; SURVIVAL; THERAPY Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/27759